HCV peptide (C5A), an amphipathic α-helical peptide of hepatitis virus C, is an activator of N-formyl peptide receptor in human phagocytes

Journal of Immunology

Volumn 186, Issue 4, 2011, Pages 2087-2094

  Lin, Qing ^a   Fang, Dan ^a   Hou, Xinwei ^b   Le, Yingying ^b   Fang, Jiazhu ^a   Wen, Feng ^a   Gong, Wanghua ^c   Chen, Keqiang ^d   Wang, Ji Ming ^d   Su, Shao Bo ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c SAIC FREDERICK INC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CHEMOATTRACTANT; FORMYLPEPTIDE RECEPTOR; G PROTEIN COUPLED RECEPTOR; HEPATITIS C VIRUS NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5A; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIVIRAL ACTIVITY; ARTICLE; CALCIUM MOBILIZATION; CELL INFILTRATION; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INNATE IMMUNITY; MOUSE; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; FEMALE; HEK293 CELLS; HUMANS; IMMUNITY, INNATE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; MONOCYTES; PEPTIDE FRAGMENTS; PHAGOCYTES; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RATS; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LIPOXIN; VIRAL NONSTRUCTURAL PROTEINS;

EID: 79951845571     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002340     Document Type: Article

References (42)

1. Viola, A., and A. D. Luster. 2008. Chemokines and their receptors: drug targets in immunity and inflammation. Annu. Rev. Pharmacol. Toxicol. 48: 171-197.
2. Sahin, H., C. Trautwein, and H.E. Wasmuth. 2010. Functional role of chemokines in liver disease models. Nat. Rev. Gastroenterol. Hepatol. 7: 682-690.
3. Ye, R. D., F. Boulay, J. M. Wang, C. Dahlgren, C. Gerard, M. Parmentier, C. N. Serhan, and P. M. Murphy. 2009. International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol. Rev. 61: 119-161.
4. Zhou, Y., X. Bian, Y. Le, W. Gong, J. Hu, X. Zhang, L. Wang, P. Iribarren, R. Salcedo, O. M. Howard, et al. 2005. Formylpeptide receptor FPR and the rapid growth of malignant human gliomas. J. Natl. Cancer Inst. 97: 823-835.
5. Wang, J. M., X. Deng, W. Gong, and S. Su. 1998. Chemokines and their role in tumor growth and metastasis. J. Immunol. Methods 220: 1-17. (Pubitemid 28527062)
6. Kim, S. D., J. M. Kim, S. H. Jo, H. Y. Lee, S. Y. Lee, J. W. Shim, S. K. Seo, J. Yun, and Y. S. Bae. 2009. Functional expression of formyl peptide receptor family in human NK cells. J. Immunol. 183: 5511-5517.
7. Su, S. B., W. H. Gong, J. L. Gao, W. P. Shen, M. C. Grimm, X. Deng, P. M. Murphy, J. J. Oppenheim, and J. M. Wang. 1999. T20/DP178, an ectodomain peptide of human immunodeficiency virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor. Blood 93: 3885-3892.
8. Su, S. B., J. Gao, W. Gong, N. M. Dunlop, P. M. Murphy, J. J. Oppenheim, and J. M. Wang. 1999. T21/DP107, A synthetic leucine zipper-like domain of the HIV-1 envelope gp41, attracts and activates human phagocytes by using G-protein-coupled formyl peptide receptors. J. Immunol. 162: 5924-5930.
9. Rabiet, M. J., E. Huet, and F. Boulay. 2005. Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR. Eur. J. Immunol. 35: 2486-2495.
10. Zhang, Q., M. Raoof, Y. Chen, Y. Sumi, T. Sursal, W. Junger, K. Brohi, K. Itagaki, and C. J. Hauser. 2010. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464: 104-107.
11. Xia, S. H., L. P. Hu, H. Hu, W. T. Ying, X. Xu, Y. Cai, Y. L. Han, B. S. Chen, F. Wei, X. H. Qian, et al. 2002. Three isoforms of annexin I are preferentially expressed in normal esophageal epithelia but down-regulated in esophageal squamous cell carcinomas. Oncogene 21: 6641-6648. (Pubitemid 35177043)
12. Sun, R., P. Iribarren, N. Zhang, Y. Zhou, W. Gong, E. H. Cho, S. Lockett, O. Chertov, F. Bednar, T. J. Rogers, et al. 2004. Identification of neutrophil granule protein cathepsin G as a novel chemotactic agonist for the G protein-coupled formyl peptide receptor. J. Immunol. 173: 428-436. (Pubitemid 38797369)
13. Le, Y., P. M. Murphy, and J. M. Wang. 2002. Formyl-peptide receptors revisited. Trends Immunol. 23: 541-548.
14. Le, Y., J. J. Oppenheim, and J. M. Wang. 2001. Pleiotropic roles of formyl peptide receptors. Cytokine Growth Factor Rev. 12: 91-105.
15. Le, Y., J. M. Wang, X. Liu, Y. Kong, X. Hou, L. Ruan, and H. Mou. 2007. Biologically active peptides interacting with the G protein-coupled formylpeptide receptor. Protein Pept. Lett. 14: 846-853.
16. Rescher, U., A. Danielczyk, A. Markoff, and V. Gerke. 2002. Functional activation of the formyl peptide receptor by a new endogenous ligand in human lung A549 cells. J. Immunol. 169: 1500-1504. (Pubitemid 34809196)
17. McCoy, R., D. L. Haviland, E. P. Molmenti, T. Ziambaras, R. A. Wetsel, and D. H. Perlmutter. 1995. N-formylpeptide and complement C5a receptors are expressed in liver cells and mediate hepatic acute phase gene regulation. J. Exp. Med. 182: 207-217.
18. Shields, P. L., C. M. Morland, M. Salmon, S. Qin, S. G. Hubscher, and D. H. Adams. 1999. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J. Immunol. 163: 6236-6243.
19. Larrubia, J. R., S. Benito-Martínez, M. Calvino, E. Sanz-de-Villalobos, and T. Parra-Cid. 2008. Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J. Gastroenterol. 14: 7149-7159.
20. Zeremski, M., L. M. Petrovic, and A. H. Talal. 2007. The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. J. Viral Hepat. 14: 675-687.
21. Lichterfeld, M., L. Leifeld, H. D. Nischalke, J. K. Rockstroh, L. Hess, T. Sauerbruch, and U. Spengler. 2002. Reduced CC chemokine receptor (CCR) 1 and CCR5 surface expression on peripheral blood T lymphocytes from patients with chronic hepatitis C infection. J. Infect. Dis. 185: 1803-1807.
22. Cicinnati, V. R., J. Kang, G. C. Sotiropoulos, P. Hilgard, A. Frilling, C. E. Broelsch, G. Gerken, and S. Beckebaum. 2008. Altered chemotactic response of myeloid and plasmacytoid dendritic cells from patients with chronic hepatitis C: role of alpha interferon. J. Gen. Virol. 89: 1243-1253.
23. Sillanpää, M., P. Kaukinen, K. Melén, and I. Julkunen. 2008. Hepatitis C virus proteins interfere with the activation of chemokine gene promoters and downregulate chemokine gene expression. J. Gen. Virol. 89: 432-443.
24. Kaukinen, P., M. Sillanpää, S. Kotenko, R. Lin, J. Hiscott, K. Melén, and I. Julkunen. 2006. Hepatitis C virus NS2 and NS3/4A proteins are potent inhibitors of host cell cytokine/chemokine gene expression. Virol. J. 3: 66.
25. Hidajat, R., M. Nagano-Fujii, L. Deng, and H. Hotta. 2004. Cleavage of the hepatitis C virus NS5A protein by caspase-3 in the interferon sensitivity-determining region in a sequence-dependent manner. Kobe J. Med. Sci. 50: 153-166.
26. Kalamvoki, M., U. Georgopoulou, and P. Mavromara. 2006. The NS5A protein of the hepatitis C virus genotype 1a is cleaved by caspases to produce C-terminal-truncated forms of the protein that reside mainly in the cytosol. J. Biol. Chem. 281: 13449-13462.
27. Kalamvoki, M., and P. Mavromara. 2004. Calcium-dependent calpain proteases are implicated in processing of the hepatitis C virus NS5A protein. J. Virol. 78: 11865-11878. (Pubitemid 39390773)
28. Sauter, D., K. Himmelsbach, M. Kriegs, M. Carvajal Yepes, and E. Hildt. 2009. Localization determines function: N-terminally truncated NS5A fragments accumulate in the nucleus and impair HCV replication. J. Hepatol. 50: 861-871.
29. Cheng, G., A. Montero, P. Gastaminza, C. Whitten-Bauer, S. F. Wieland, M. Isogawa, B. Fredericksen, S. Selvarajah, P. A. Gallay, M. R. Ghadiri, and F. V. Chisari. 2008. A virocidal amphipathic alpha-helical peptide that inhibits hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA 105: 3088-3093.
30. Bobardt, M. D., G. Cheng, L. de Witte, S. Selvarajah, U. Chatterji, B. E. Sanders-Beer, T. B. Geijtenbeek, F. V. Chisari, and P. A. Gallay. 2008. Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 105: 5525-5530.
31. Rothwangl, K. B., B. Manicassamy, S. L. Uprichard, and L. Rong. 2008. Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding. Virol. J. 5: 46.
32. Su, S. B., W. Gong, J. L. Gao, W. Shen, P. M. Murphy, J. J. Oppenheim, and J. M. Wang. 1999. A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J. Exp. Med. 189: 395-402.
33. Zhu, J., O. Wang, L. Ruan, X. Hou, Y. Cui, J. M. Wang, and Y. Le. 2009. The green tea polyphenol (-)-epigallocatechin-3-gallate inhibits leukocyte activation by bacterial formylpeptide through the receptor FPR. Int. Immunopharmacol. 9: 1126-1130.
34. Su, S. B., P. B. Silver, R. S. Grajewski, R. K. Agarwal, J. Tang, C. C. Chan, and R. R. Caspi. 2005. Essential role of the MyD88 pathway, but nonessential roles of TLRs 2, 4, and 9, in the adjuvant effect promoting Th1-mediated autoimmunity. J. Immunol. 175: 6303-6310.
35. Ali, H., R. M. Richardson, E. D. Tomhave, J. R. Didsbury, and R. Snyderman. 1993. Differences in phosphorylation of formylpeptide and C5a chemoattractant receptors correlate with differences in desensitization. J. Biol. Chem. 268: 24247-24254.
36. Huang, J., K. Chen, W. Gong, Y. Zhou, Y. Le, X. Bian, and J. M. Wang. 2008. Receptor "hijacking" by malignant glioma cells: a tactic for tumor progression. Cancer Lett. 267: 254-261.
37. Huang, J., K. Chen, J. Huang, W. Gong, N. M. Dunlop, O. M. Howard, X. Bian, Y. Gao, and J. M. Wang. 2009. Regulation of the leucocyte chemoattractant receptor FPR in glioblastoma cells by cell differentiation. Carcinogenesis 30: 348-355.
38. Alkhatib, G. 2009. The biology of CCR5 and CXCR4. Curr. Opin. HIV AIDS 4: 96-103.
39. Kusano, F., Y. Tanaka, F. Marumo, and C. Sato. 2000. Expression of C-C chemokines is associated with portal and periportal inflammation in the liver of patients with chronic hepatitis C. Lab. Invest. 80: 415-422.
40. Apolinario, A., P. L. Majano, E. Alvarez-Pérez, A. Saez, C. Lozano, J. Vargas, and C. García-Monzón. 2002. Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease. Am. J. Gastroenterol. 97: 2861-2870.
41. Murdoch, C., and A. Finn. 2000. Chemokine receptors and their role in inflammation and infectious diseases. Blood 95: 3032-3043. (Pubitemid 30321151)
42. Moser, B., and P. Loetscher. 2001. Lymphocyte traffic control by chemokines. Nat. Immunol. 2: 123-128.